Hepatx
Develops stem-cell therapies for liver disease.
Raising now
OpenRaising on Wefunder ↗
- As of Nov 1, 2026
- $61,161 raised from 55 investors
- Target, as of Nov 1, 2026
- $1,235,000
- Maximum, as of Nov 1, 2026
- $1,235,000
- Closes
- Apr 30, 2027
As Wefunder reports them, as of Nov 1, 2026
- Security
- safe
- Pro rata
- No
- Uncapped
- No
- Valuation cap
- $17,500,000
- Most favored nation
- No
- Exemption
- Reg CF
- Minimum
- $100
From the SEC Form C
- Security (as filed)
- Simple Agreement for Future Equity (SAFE)
- Price
- $1.00
- Filed
- Sep 14, 2026
- Incorporated in
- DE
- Employees
- 2
- Revenue, last fiscal year
- $0
- Net income, last fiscal year
- -$246,314
EarlySignals' view, not the portal's
Our potential score, six-dimension radar and research are for members.
Figures are the portal's own, as of the date shown. Not investment advice; EarlySignals takes no payment from issuers or portals.